An IRB Transformation: Increasing Quality and Efficiency Using Existing Resources

Introduction A debate is currently underway on whether local IRB review is better than external IRB review. Much of the debate surrounds the fact external IRBs have the advantage of quicker turnaround times, plus funds devoted solely to customer service. Many university IRBs have found it difficult to meet this challenge. (Whitney et al., 2008). The following inquiry examines how one IRB adopted external IRB practices and made themselves competitive with their external colleagues, settling some of the debate. By doing this, they were able to maintain high quality local review, while increasing efficiency and levels of service. The concerns over IRB efficiency across the country have prompted a series of articles and opinion papers on the potential for a redesign of the IRB review system, utilizing a single IRB for all multi-site research. (Wechsler, 2007). Debates over whether a central IRB model is practical and whether the use of for-profit IRBs would decrease the quality of review due to the financial stake those entities have in the volume of reviews have been carried out in the literature. (Lemmens & Freedman, 2000). During the summer of 2011, an Advanced Notice of Proposed Rule Making (ANPRM) was released by the Office for Human Research Protections (OHRP) which included a call for input on how a central IRB model for multisite research might be designed in order to reduce the bottlenecks caused by lengthy IRB reviews at each research site. (Federal Register, 2011). The national discussion on whether local or central Institutional Review Boards (IRB's) better serve to protect human research participants has raised questions as to whether the use of central boards to the exclusion of any local review would eliminate the consideration of local context and prevent institutions from evaluating the ability of their research program to safely conduct the study. (Wechsler, 2007). In addition, a long standing concern about the quality of review conducted by for-profit IRBs has made some in academic medicine skeptical of reliance of these entities for oversight of clinical trials. (Lemmens & Freedman, 2000). Improving IRB efficiency and review quality has been a constant goal for the WFSM IRB, but in 2011 there were institutional priority shifts, and changes in leadership that focused the attention of research support leadership on finding ways to overhaul the support mechanisms immediately so that clinical research capacity at the institution could be increased without the need to hire new staff members or increasing budgets. It was also important that the quality of review and service to investigators remain high. The Impetus for Change In July 2011 Wake Forest School of Medicine (WFSM) welcomed a new Dean. Following the Dean's arrival, the priorities of the research program were reassessed in the light of a recently developed strategic plan for the academic medical center. One of the new priorities set by upper administration was the growth of the clinical trials research program. To make this possible, the Dean called on research administration to find ways of increasing capacity by decreasing turn-around time. Turn-around time in July 2011 for initial human research submissions requiring full board review by the Wake Forest School of Medicine IRB was averaging approximately 45 days. This was comparable with the national average of 46 days cited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) as the average approval time of accredited IRBs who completed their latest performance metrics survey (AAHRPP, 2011). Most investigators were not dissatisfied with the review times at WFSM, but the Dean previously served in an Academic Medical Center that utilized a central IRB for industry sponsored clinical trials in order to achieve a top level of efficiency. WFSM IRB leaders knew that in order to meet the Dean's expectations, efficiency needed to meet commercial IRB levels without any reduction in the quality and thoroughness of protocol review. …

[1]  Robert J. Volk,et al.  Principal Investigator Views of the IRB System , 2008, International journal of medical sciences.

[2]  T. Lemmens,et al.  Ethics Review for Sale? Conflict of Interest and Commercial Research Review Boards , 2000, The Milbank quarterly.